Story code: ST-001180
Part 3: The True Ledger
I stood up from my terminal, my pulse hammering in my throat. The security camera at the end of the administrative corridor swept its lens from side to side in a slow, mechanical rhythm. I knew the night guard was currently conducting his hourly sweep of the building’s lower level, leaving me a brief window to access the executive offices without triggering an inquiry.
I walked down the quiet, carpeted hallway toward Richard’s private office. The clinic was silent, the only sound the low hum of the climate control system pushing sterile air through the ceiling vents. My badge clicked against the electronic lock of his door. The indicator light flashed green, and the lock disengaged with a heavy click.
Inside, the office smelled of expensive leather and polished wood. I didn’t turn on the overhead lights; the ambient glow from the glass partitions of the main hallway was enough to guide me. I bypassed the filing cabinets and went straight to the heavy desk. In the bottom drawer, underneath a stack of glossy promotional brochures for Vance Therapeutics, sat a small steel box. Richard kept his physical backup security tokens there-a security measure he insisted on to keep critical data off the shared network. I found the desk key in a brass tray, unlocked the box, and pulled out the blue hardware security key labeled VT-ARCHIVE-01.
I locked the drawer, closed the office door behind me, and walked back to the Data Verification Suite. My hands shook slightly as I slotted the hardware key into my workstation. A progress bar appeared, decrypting the secure network archives of Vance Therapeutics from three years ago. I opened the folder containing the historical patient trial cohorts.
There, cataloged under his startup’s proprietary file structure, was my mother’s name.
I cross-referenced the dates. My mother’s experimental vector injection took place on October 14th. The clinical ledger showed that Vance Therapeutics had faced a critical regulatory deadline on October 30th. If they did not submit safety data for their proprietary gene-delivery vector by that date, their master patent would expire, rendering their entire molecular library worthless to future investors.
I pulled up the corporate funding ledgers. On October 17th, three days after my mother’s treatment showed initial success, Richard had submitted the clinical data to the patent office. On October 22nd, his company secured a twelve-million-dollar investment round based entirely on that filing.
The seven hundred thousand dollars he claimed to have spent out of pocket to save my mother had never been a personal sacrifice. It was a corporate investment using an unauthorized human subject to rescue his failing startup from immediate bankruptcy. He hadn’t saved her; her survival had saved his entire company.
I exported the audit trails, the patent filing timestamps, and the original ledger entries, compiling them into a single secure file. I linked this file directly to the validation engine of Lab Report 109-A. As the transfer completed, the electronic lock of the suite clicked. The handle turned. I looked up to see Richard standing in the doorway, his coat damp from the rain outside, his eyes scanning the glowing terminal screens.